Verastem announces common stock offering, no amount given

Verastem Oncology announced that it intends to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering. Verastem Oncology intends to use the net proceeds from the proposed public offering for (i) continued research and development of its product candidates (ii) potential launch of avutometinib and defactinib in low-grade serous ovarian cancer, and (iii) working capital and other general corporate purposes. RBC Capital Markets and Cantor are acting as joint book-running managers and representatives of the underwriters for the proposed offering.